Catalio Capital Management’s Metagenomi Therapeutics MGX Stock Holding History

Catalio Capital Management’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$630K	Hold	528,993	–	–	0.12%	37
2026 Q1	$709K	Hold	528,993	–	–	0.15%	38
2025 Q4	$857K	Hold	528,993	–	–	0.15%	42
2025 Q3	$1.25M	Hold	528,993	–	–	0.23%	32
2025 Q2	$783K	Hold	528,993	–	–	0.16%	34
2025 Q1	$719K	Hold	528,993	–	–	0.18%	30
2024 Q4	$1.91M	Buy	+528,993	New	+$1.28M	0.42%	27

Other funds holding MGX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Catalio Capital Management's MGX Position: Q2 2026 in Review

Catalio Capital Management held its Metagenomi Therapeutics (MGX) position steady in Q2 2026 at 528,993 shares worth $630K. The position accounts for 0.12% of the portfolio, ranked #37.

Catalio Capital Management first reported a position in MGX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.91M in Q4 2024. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

Catalio Capital Management held 528,993 shares of Metagenomi Therapeutics worth $630K as of Q2 2026.
Catalio Capital Management left its Metagenomi Therapeutics share count unchanged in Q2 2026.
Metagenomi Therapeutics made up 0.12% of Catalio Capital Management's portfolio in Q2 2026, its #37 holding.
Catalio Capital Management first reported a position in Metagenomi Therapeutics in Q4 2024 and has held it in 7 quarters since.
Catalio Capital Management's Metagenomi Therapeutics position peaked at $1.91M in Q4 2024.
43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.